Veru to present at the 2024 cantor global healthcare conference

Miami, fl, sept. 11, 2024 (globe newswire) -- veru inc. (nasdaq: veru), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that mitchell steiner, m.d., chairman, president and chief executive officer of veru, will present a corporate update with a focus on the progress of veru's phase 2b clinical development program of enobosarm to augment fat loss and to avoid muscle loss when combined with glp-1 drugs for weight loss at the 2024 cantor global healthcare conference on september 18th at 1:55 pm – 2:25 pm eastern time.
VERU Ratings Summary
VERU Quant Ranking